Advertisement

Posttransplant Lymphoproliferative Disorder

  • Margaret L. Gulley
Chapter
Part of the Molecular Pathology Library book series (MPLB, volume 4)

Abstract

Posttransplant lymphoproliferative disorder (PTLD) is a rare, life-threatening neoplasm occurring after hematopoietic stem cell or solid organ transplant. The pathobiology of PTLD is distinct from conventional lymphoma, in that immunosuppression and Epstein–Barr virus (EBV) are critical cofactors in tumor development, and these features also afford unique strategies for targeted therapy.

Keywords

Anaplastic Large Cell Lymphoma Posttransplant Lymphoproliferative Disorder Preemptive Therapy Florid Follicular Hyperplasia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Schubert S, Renner C, Hammer M, et al. Relationship of immunosuppression to Epstein–Barr viral load and lymphoproliferative disease in pediatric heart transplant patients. J Heart Lung Transplant. 2008;27:100–105.CrossRefPubMedGoogle Scholar
  2. 2.
    Kinch A, Oberg G, Arvidson J, Falk KI, Linde A, Pauksens K. Post-transplant lymphoproliferative disease and other Epstein–Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction. Scand J Infect Dis. 2007;39:235–244.CrossRefPubMedGoogle Scholar
  3. 3.
    EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.1. Cancer risk after renal transplantation. Post-transplant lymphoproliferative disease (PTLD): prevention and treatment. Nephrol Dial Transplant. 2002;17(suppl 4):31–33.Google Scholar
  4. 4.
    Chadburn A, Chen JM, Hsu DT, et al. The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevant. Cancer. 1998;82:1978–1987.CrossRefPubMedGoogle Scholar
  5. 5.
    Tsao L, Hsi ED. The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders. Arch Pathol Lab Med. 2007;131:1209–1218.PubMedGoogle Scholar
  6. 6.
    Swerdlow SH, Webber SA, Chadburn A, Ferry JA. Posttransplant lymphoproliferative disorders. In: SH Swerdlow, ed. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008:343–349.Google Scholar
  7. 7.
    Semakula B, Rittenbach JV, Wang J. Hodgkin lymphoma-like posttransplantation lymphoproliferative disorder. Arch Pathol Lab Med. 2006;130:558–560.PubMedGoogle Scholar
  8. 8.
    Vakiani E, Nandula SV, Subramaniyam S, et al. Cytogenetic analysis of B-cell posttransplant lymphoproliferations validates the World Health Organization classification and suggests inclusion of florid follicular hyperplasia as a precursor lesion. Hum Pathol. 2007;38:315–325.CrossRefPubMedGoogle Scholar
  9. 9.
    Capello D, Rossi D, Gaidano G. Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis. Hematol Oncol. 2005;23:61–67.CrossRefPubMedGoogle Scholar
  10. 10.
    Kaleem Z, Hassan A, Pathan MH, White G. Flow cytometric evaluation of posttransplant B-cell lymphoproliferative disorders. Arch Pathol Lab Med. 2004;128:181–186.PubMedGoogle Scholar
  11. 11.
    Dunphy CH, Gardner LJ, Grosso LE, Evans HL. Flow cytometric immunophenotyping in posttransplant lymphoproliferative disorders. Am J Clin Pathol. 2002;117:24–28.PubMedGoogle Scholar
  12. 12.
    Kaplan MA, Ferry JA, Harris NL, Jacobson JO. Clonal analysis of posttransplant lymphoproliferative disorders, using both episomal Epstein–Barr virus and immunoglobulin genes as markers. Am J Clin Pathol. 1994;101:590–596.PubMedGoogle Scholar
  13. 13.
    Gulley ML, Raphael M, Lutz CT, Ross DW, Raab-Traub N. Epstein–Barr virus integration in human lymphomas and lymphoid cell lines. Cancer. 1992;70:185–191.CrossRefPubMedGoogle Scholar
  14. 14.
    Locker J, Nalesnik M. Molecular genetic analysis of lymphoid tumors arising after organ transplantation. Am J Pathol. 1989;135:977–987.PubMedGoogle Scholar
  15. 15.
    Ryan JL, Kaufmann WK, Raab-Traub N, Oglesbee SE, Carey LA, Gulley ML. Clonal evolution of lymphoblastoid cell lines. Lab Invest. 2006;86:1193–1200.CrossRefPubMedGoogle Scholar
  16. 16.
    Young LS, Murray PG. Epstein–Barr virus and oncogenesis: from latent genes to tumours. Oncogene. 2003;22:5108–5121.CrossRefPubMedGoogle Scholar
  17. 17.
    Shaknovich R, Basso K, Bhagat G, et al. Identification of rare Epstein–Barr virus infected memory B cells and plasma cells in non-monomorphic post-transplant lymphoproliferative disorders and the signature of viral signaling. Haematologica. 2006;91:1313–1320.PubMedGoogle Scholar
  18. 18.
    Kaiser C, Laux G, Eick D, Jochner N, Bornkamm GW, Kempkes B. The proto-oncogene c-myc is a direct target gene of Epstein–Barr virus nuclear antigen 2. J Virol. 1999;73:4481–4484.PubMedGoogle Scholar
  19. 19.
    Niedobitek G, Herbst H. In situ detection of Epstein–Barr virus and phenotype determination of EBV-infected cells. Methods Mol Biol. 2006;326:115–137.PubMedGoogle Scholar
  20. 20.
    Gulley ML, Tang W. Laboratory assays for Epstein–Barr virus-related disease. J Mol Diagn. 2008;10:279–292.CrossRefPubMedGoogle Scholar
  21. 21.
    Delecluse HJ, Kremmer E, Rouault JP, Cour C, Bornkamm G, Berger F. The expression of Epstein–Barr virus latent proteins is related to the pathological features of post-transplant lymphoproliferative disorders. Am J Pathol. 1995;146:1113–1120.PubMedGoogle Scholar
  22. 22.
    Djokic M, Le Beau MM, Swinnen LJ, et al. Post-transplant lymphoproliferative disorder subtypes correlate with different recurring chromosomal abnormalities. Genes Chromosomes Cancer. 2006;45:313–318.CrossRefPubMedGoogle Scholar
  23. 23.
    Poirel HA, Bernheim A, Schneider A, et al. Characteristic pattern of chromosomal imbalances in posttransplantation lymphoproliferative disorders: correlation with histopathological subcategories and EBV status. Transplantation. 2005;80:176–184.CrossRefPubMedGoogle Scholar
  24. 24.
    Cerri M, Capello D, Muti G, et al. Aberrant somatic hypermutation in post-transplant lymphoproliferative disorders. Br J Haematol. 2004;127:362–364.CrossRefPubMedGoogle Scholar
  25. 25.
    Rinaldi A, Kwee I, Poretti G, et al. Comparative genome-wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas. Br J Haematol. 2006;134:27–36.CrossRefPubMedGoogle Scholar
  26. 26.
    Okubo M, Tsurukubo Y, Higaki T, et al. Clonal chromosomal aberrations accompanied by strong telomerase activity in immortalization of human B-lymphoblastoid cell lines transformed by Epstein–Barr virus. Cancer Genet Cytogenet. 2001;129:30–34.CrossRefPubMedGoogle Scholar
  27. 27.
    Rossi D, Gaidano G, Gloghini A, et al. Frequent aberrant promoter hypermethylation of 06-methylguanine-DNA methyltransferase and death-associated protein kinase genes in immunodeficiency-related lymphomas. Br J Haematol. 2003;123:475–478.CrossRefPubMedGoogle Scholar
  28. 28.
    Craig FE, Johnson LR, Harvey SA, et al. Gene expression profiling of Epstein–Barr virus-positive and -negative monomorphic B-cell posttransplant lymphoproliferative disorders. Diagn Mol Pathol. 2007;16:158–168.CrossRefPubMedGoogle Scholar
  29. 29.
    Cesarman E, Chadburn A, Liu YF, Migliazza A, Dalla-Favera R, Knowles DM. BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome. Blood. 1998;92:2294–2302.PubMedGoogle Scholar
  30. 30.
    Swerdlow SH. T-cell and NK-cell posttransplantation lymphoproliferative disorders. Am J Clin Pathol. 2007;127:887–895.CrossRefPubMedGoogle Scholar
  31. 31.
    Draoua HY, Tsao L, Mancini DM, Addonizio LJ, Bhagat G, Alobeid B. T-cell post-transplantation lymphoproliferative disorders after cardiac transplantation: a single institutional experience. Br J Haematol. 2004;127:429–432.CrossRefPubMedGoogle Scholar
  32. 32.
    Dotti G, Fiocchi R, Motta T, et al. Epstein–Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. Transplantation. 2000;69:827–833.CrossRefPubMedGoogle Scholar
  33. 33.
    Green M. Management of Epstein–Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation. Am J Transplant. 2001;1:103–108.PubMedGoogle Scholar
  34. 34.
    Wagner HJ, Wessel M, Jabs W, et al. Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein–Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation. 2001;72:1012–1019.CrossRefPubMedGoogle Scholar
  35. 35.
    Niesters HG, van Esser J, Fries E, Wolthers KC, Cornelissen J, Osterhaus AD. Development of a real-time quantitative assay for detection of Epstein–Barr virus. J Clin Microbiol. 2000;38:712–715.PubMedGoogle Scholar
  36. 36.
    Orentas RJ, Schauer DW Jr, Ellis FW, Walczak J, Casper JT, Margolis DA. Monitoring and modulation of Epstein–Barr virus loads in pediatric transplant patients. Pediatr Transplant. 2003;7:305–314.CrossRefPubMedGoogle Scholar
  37. 37.
    D’Antiga L, Del Rizzo M, Mengoli C, Cillo U, Guariso G, Zancan L. Sustained Epstein–Barr virus detection in paediatric liver transplantation. Insights into the occurrence of late PTLD. Liver Transpl. 2007;13:343–348.CrossRefPubMedGoogle Scholar
  38. 38.
    Green M, Michaels MG, Webber SA, Rowe D, Reyes J. The management of Epstein–Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients. Pediatr Transplant. 1999;3:271–281.CrossRefPubMedGoogle Scholar
  39. 39.
    Aalto SM, Juvonen E, Tarkkanen J, et al. Epstein–Barr viral load and disease prediction in a large cohort of allogeneic stem cell transplant recipients. Clin Infect Dis. 2007;45:1305–1309.CrossRefPubMedGoogle Scholar
  40. 40.
    Lee TC, Savoldo B, Rooney CM, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant. 2005;5:2222–2228.CrossRefPubMedGoogle Scholar
  41. 41.
    van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein–Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood. 2002;99:4364–4369.CrossRefPubMedGoogle Scholar
  42. 42.
    Bakker NA, Verschuuren EA, Erasmus ME, et al. Epstein–Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression. Transplantation. 2007;83:433–438.CrossRefPubMedGoogle Scholar
  43. 43.
    Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006;6:262–274.CrossRefPubMedGoogle Scholar
  44. 44.
    Ahya VN, Douglas LP, Andreadis C, et al. Association between elevated whole blood Epstein–Barr virus (EBV)-encoded RNA EBV polymerase chain reaction and reduced incidence of acute lung allograft rejection. J Heart Lung Transplant. 2007;26:839–844.CrossRefPubMedGoogle Scholar
  45. 45.
    Bingler MA, Feingold B, Miller SA, et al. Chronic high Epstein–Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease/lymphoma in children. Am J Transplant. 2008;8:442–445.CrossRefPubMedGoogle Scholar
  46. 46.
    Li L, Chaudhuri A, Weintraub LA, et al. Subclinical cytomegalovirus and Epstein–Barr virus viremia are associated with adverse outcomes in pediatric renal transplantation. Pediatr Transplant. 2007;11:187–195.CrossRefPubMedGoogle Scholar
  47. 47.
    Sebelin-Wulf K, Nguyen TD, Oertel S, et al. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD. Transpl Immunol. 2007;17:203–210.CrossRefPubMedGoogle Scholar
  48. 48.
    Qu L, Green M, Webber S, Reyes J, Ellis D, Rowe D. Epstein–Barr virus gene expression in the peripheral blood of transplant recipients with persistent circulating virus loads. J Infect Dis. 2000;182:1013–1021.CrossRefPubMedGoogle Scholar
  49. 49.
    Lee TC, Goss JA, Rooney CM, et al. Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection. Clin Transplant. 2006;20:689–694.CrossRefPubMedGoogle Scholar
  50. 50.
    Smets F, Latinne D, Bazin H, et al. Ratio between Epstein–Barr viral load and anti-Epstein–Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation. 2002;73:1603–1610.CrossRefPubMedGoogle Scholar
  51. 51.
    Weinberger B, Plentz A, Weinberger KM, Hahn J, Holler E, Jilg W. Quantitation of Epstein–Barr virus mRNA using reverse transcription and real-time PCR. J Med Virol. 2004;74:612–618.CrossRefPubMedGoogle Scholar
  52. 52.
    Meij P, van Esser JW, Niesters HG, et al. Impaired recovery of Epstein–Barr virus (EBV) – specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood. 2003;101:4290–4297.CrossRefPubMedGoogle Scholar
  53. 53.
    Carpentier L, Tapiero B, Alvarez F, Viau C, Alfieri C. Epstein–Barr virus (EBV) early-antigen serologic testing in conjunction with peripheral blood EBV DNA load as a marker for risk of posttransplantation lymphoproliferative disease. J Infect Dis. 2003;188:1853–1864.CrossRefPubMedGoogle Scholar
  54. 54.
    Yamashita N, Kimura H, Morishima T. Virological aspects of Epstein–Barr virus infections. Acta Med Okayama. 2005;59:239–246.PubMedGoogle Scholar
  55. 55.
    Bhaduri-McIntosh S, Rotenberg MJ, Gardner B, Robert M, Miller G. Repertoire and frequency of immune cells reactive to Epstein–Barr virus-derived autologous lymphoblastoid cell lines. Blood. 2008;111:1334–1343.CrossRefPubMedGoogle Scholar
  56. 56.
    Gulley ML, Swinnen LJ, Plaisance KT Jr, Schnell C, Grogan TM, Schneider BG. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy. Transplantation. 2003;76:959–964.CrossRefPubMedGoogle Scholar
  57. 57.
    Verschuuren EA, Stevens SJ, van Imhoff GW, et al. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. Transplantation. 2002;73:100–104.CrossRefPubMedGoogle Scholar
  58. 58.
    Brauninger A, Schmitz R, Bechtel D, Renne C, Hansmann ML, Kuppers R. Molecular biology of Hodgkin’s and Reed/Sternberg cells in Hodgkin’s lymphoma. Int J Cancer. 2006;118:1853–1861.CrossRefPubMedGoogle Scholar
  59. 59.
    Savoldo B, Goss JA, Hammer MM, et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood. 2006;108:2942–2949.CrossRefPubMedGoogle Scholar
  60. 60.
    Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007;110:1123–1131.CrossRefPubMedGoogle Scholar
  61. 61.
    Green M, Cacciarelli TV, Mazariegos GV, et al. Serial measurement of Epstein–Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease. Transplantation. 1998;66:1641–1644.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Margaret L. Gulley
    • 1
  1. 1.University of North Carolina at Chapel HillChapel HillUSA

Personalised recommendations